MS 282A

Drug Profile

MS 282A

Latest Information Update: 07 Jun 2001

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Class Anti-ischaemics; Antiasthmatics; Bronchodilators; Cardiotonics; Vasodilators
  • Mechanism of Action Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Ischaemic heart disorders

Most Recent Events

  • 07 Jun 2001 Discontinued-Preclinical for Asthma in Japan (Unknown route)
  • 07 Jun 2001 Discontinued-Preclinical for Ischaemic heart disorders in Japan (Unknown route)
  • 31 Aug 1998 No-Development-Reported for Asthma in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top